西妥昔单抗联合FOLFIRI化疗方案治疗晚期结肠癌疗效观察  

To Observe the Efficacy of Cetuximab Combined with FOLFIRI Chemotherapy in the Treatment of Advanced Colorectal Cancer Treatment

作　　者：杜丽坤[1] 王霄鹏[1] 陈克富[1] 

机构地区：[1]吉林省通化市第二人民医院血液肿瘤科,吉林通化134003

出　　处：《中外医疗》2016年第22期117-118,共2页China & Foreign Medical Treatment

摘　　要：目的探析西妥昔单抗联合FOLFIRI化疗方案治疗晚期结肠癌的临床效果。方法整群选取该院2011—2015年期间收治的65例晚期结肠癌患者,按照不同治疗方法分成两组,即单一组(n=32,给予FOLFIRI化疗)、联合组(n=33,给予西妥昔单抗联合FOLFIRI化疗),对2组患者的临床疗效及不良反应情况进行评比。结果联合组患者的临床疗效为69.7%,相较于单一组患者的43.7%,组间比较差异有统计学意义(P<0.05)。在恶心呕吐、血小板减少、白细胞减少、肝功能受损方面,两组比较差异无统计学意义(P>0.05);但联合组皮疹发生率明显高于单一组(P<0.05)。结论在晚期结肠癌治疗中,给予西妥昔单抗联合FOLFIRI化疗方案治疗,临床效果非常确切,值得临床广泛应用与普及。Objective The clinical effect of cetuximab combined with FOLFIRI chemotherapy in the treatment of advanced colorectal cancer. Methods Group selected in our hospital from 2011 to 2015 admitted during the period of 65 cases of advanced colon cancer patients, according to the different treatment method is divided into two groups, namely single group（n = 32, give the FOLFIRI chemotherapy）, combination group（n = 33, received cetuximab plus FOLFIRI chemotherapy）,clinical efficacy and adverse reactions of two groups of patients appraisal. Results The clinical efficacy of combined group patients was 69.7%, compared to the single group 43.7%, there was significant difference between the groups（P〈0.05）. In nausea and vomiting, thrombocytopenia, leukopenia, liver function damage, two groups had no statistically significant difference（P〉0.05）; but the combined group rash incidence was significantly higher than that of single group（P〈0.05）. Conclusion In the treatment of patients with advanced colon cancer, the clinical effect is very accurate, and it is worthy to be widely used and popularized.

关 键 词：西妥昔单抗 FOLFIRI化疗 晚期结肠癌 临床疗效 

分 类 号：R5[医药卫生—内科学]